People on the move.
Fremont, CA (Aug. 21)—
chief executive Mark McDade will resign by the end of 2007. An internal investigation found no credible evidence of improper
personal conduct or breach of fiduciary duty.
Stockholm, Sweden (Aug. 17)— Orexo
appointed three senior executives: Mats Eriksson, PhD, to vice-president of research and clinical development and medical
director; Christina Ståhl, MSc. Pharm, to vice-president of regulatory affairs; and Anne Marie Ciupitu, MSc, PhD, to director
of quality assurance and quality control
Woburn, MA (Aug. 15)—
BioVex, a biotechnology company developing clinical-stage treatments, appointed Dr. Thaddeus Pullano as vice-president of quality
Palo Alto, CA (Aug. 14)—
Affymax named Robert Venteicher as the company's vice-president of technical operations. In this position, Venteicher will oversee
manufacturing and process development, quality, and facility operations for Affymax.
Shanghai, China (Aug. 13)—
a provider of pharmaceutical research and development outsourcing services, appointed Edward Hu executive vice-president of
operations. Hu will report directly to Ge Li, chairman and chief executive officer of the company.
Westbrook, ME (Aug. 13)—
Artel, a provider of liquid-handling quality assurance, appointed Bjoern Carle, PhD, laboratory applications scientist.
Markham, ON, Canada (Aug. 13)—Joel Z. Melnick, MD, joined Cytochroma as vice-president of clinical and regulatory affairs. Melnick will be responsible for managing the clinical development of
Cytochroma's new Vitamin D therapies and for obtaining marketing approvals from the
US Food and Drug Administration
and Canada's Therapeutic Products Directorate.
New York (Aug. 10)—The pharmaceutical company
appointed John H. Johnson as its chief executive officer, effective August 27, 2007.
Vancouver, BC, Canada (Aug. 10)—
appointed Ross L. Senior its president and CEO.
Toronto, ON, Canada (Aug. 9)—
a consulting and contract manufacturing company, appointed David G. Leonard the Keata Pharma president for the Sydney, Nova
Scotia, Canada, and Perth, Ontario, Canada, manufacturing sites. Keata Pharma is a wholly owned subsidiary of PharmEng with
manufacturing facilities in Perth and new facilities in Sydney scheduled to open in the fourth quarter of this year.
Bridgewater, NJ (Aug. 9)—
a private biopharmaceutical company, announced a promotion and a new addition to the firm. Eleanor de Groot was promoted to
vice-president of technical operations, with increased responsibilities for all drug development and manufacturing activities
at the company. Brenda Marczi will join Sapphire as vice-president of regulatory affairs.